An in vivo inflammatory loop potentiates KRAS blockade
K. A. Arendt, G. Ntaliarda, V. Armenis, D. Kati, C. Henning, G. Giotopoulou, M. A. Pepe, L. V. Klotz, A. S. Lamort, R. A. Hatz, S. Kobold, G. T. Stathopoulos
The paper shows that KRAS-mutant tumors rely on an inflammatory loop involving C-C-motif chemokine ligand 2/interleukin-1β signaling, making them resistant to KRAS inhibitors in vivo but responsive in certain transplant models.
bioRxiv · Apr 19, 2020Cancer Biology